GSK126

For research use only. Not for use in humans.

目录号:S7061 别名: GSK2816126A, GSK2816126

GSK126 Chemical Structure

CAS No. 1346574-57-9

GSK126 (GSK2816126A, GSK2816126) 是一种有效的,高选择性EZH2 methyltransferase抑制剂,IC50为9.9 nM,对 EZH2 的选择性比其他20种人甲基转移酶高1000多倍。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2203.11 现货
RMB 1180.22 现货
RMB 3888.89 现货
RMB 8157.68 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的GSK126发表文献98篇:

产品安全说明书

Histone Methyltransferase抑制剂选择性比较

生物活性

产品描述 GSK126 (GSK2816126A, GSK2816126) 是一种有效的,高选择性EZH2 methyltransferase抑制剂,IC50为9.9 nM,对 EZH2 的选择性比其他20种人甲基转移酶高1000多倍。
靶点
EZH2 [1]
(Cell-free assay)
9.9 nM
体外研究

在体外,EZH2野生型和突变型DLBCL细胞系中,GSK126最有效地抑制H3K27me3,其次是H3K27me2。GSK126也能有效抑制EZH2突变型DLBCL细胞系的增殖,并诱导敏感细胞系中EZH2靶基因的转录激活。[1]在A687V EZH2突变细胞中,GSK126处理导致总体H3K27me3减少,强基因活化,胱天蛋白酶活化,以及增殖减少。[2]在亲代H2087细胞中,GSK126抑制VEGF-A和磷酸化Ser(473)-AK的表达,因此引起对细胞增殖,迁移和代谢的抑制。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human U87MG cells MoS0R5l1d3SxeHnjxsBie3OjeR?= MUi3NkBp MlS1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVg4VUdiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFeVVD2xJIF{e2G7LDDHTVUxRTJ6LkWg{txONg>? MnntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Nke4OVAoRjJ2N{[3PFUxRC:jPh?=
human A549 cells MkTFR5l1d3SxeHnjxsBie3OjeR?= NGexPVg4OiCq MmjpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhX1OWLUGgZZN{[XluIFfJOVA:OThwNzFOwG0v MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4N{i1NEc,OjR5Nke4OVA9N2F-
human T98G cells MoDCR5l1d3SxeHnjxsBie3OjeR?= NVzHZ4pIPzJiaB?= NFfKfGFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVQTiJIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCZU2StNUBie3OjeTygS2k2OD1zMj62JO69VS5? NXfa[GlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS3Olc5PTBpPkK0O|Y4QDVyPD;hQi=>
human Daudi cells NVz3OmxyS3m2b4TvfIlkyqCjc4PhfS=> M3\ZT|czKGh? MlzzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSIF2\GliY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFeVVD2xJIF{e2G7LDDHTVUxRTFzLkKg{txONg>? MmLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Nke4OVAoRjJ2N{[3PFUxRC:jPh?=
human PC3 cells M2O1VWN6fG:2b4jpZ:Kh[XO|YYm= NWSzdWJtPzJiaB?= MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JHdUXC1zIHHzd4F6NCCJSUWwQVkvPCEQvF2u NH7xfoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2O|g2OCd-MkS3Olc5PTB:L3G+
human U2932 cells MVXDfZRwfG:6aXRCpIF{e2G7 NXrINYg6PzJiaB?= NYPRSVJ{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTJ7M{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGfTWE0yKGG|c3H5MEBIUTVyPU[uO{DPxE1w NFzSPJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2O|g2OCd-MkS3Olc5PTB:L3G+
human HeLa cells MmDDSpVv[3Srb36gZZN{[Xl? NWn3VXF3PzJiaB?= NFvEfXlKdmirYnn0bY9vKG:oIFXaTFIhcW5iaIXtZY4hUGWOYTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hUDONMkft[VMhdGW4ZXzzJIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IFXMTXNCKG2ndHjv[EwhUUN3ME2wMlI5KM7:TT6= M{DseFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUi5NFc5Lz5{NkG4PVA4QDxxYU6=
human Pfeiffer cells NYfOfIIyS3m2b4TvfIlkyqCjc4PhfS=> M{TuflczKGh? MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQ[oVq\m[ncjDj[YxteyCneIDy[ZN{cW6pIFXaTFIhSTZ4N1egcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDXV3QuOSCjc4PhfUwhT0l3ME2wMlE5KM7:TT6= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd4N{i1NEc,OjR5Nke4OVA9N2F-
infected SF9 cells NHHPUHpDcW6maX7nJIFn\mmwaYT5JJRwKEWcSEKgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU1[5JINmdGy|IHPvMYV5eHKnc4PpcochW1WcMUKvSWVFN1KkQYC0PEBkd22ybHX4JIF{e2W|c3XkJIF{KGKrbnTpcochd2[oLYLheIUh[XRiMD60JJVOKGmwY4XiZZRm\CCob4KgNlAhdWmwczDifUBSNVSRRjDtZZN{KHOyZXP0do9u\XS{eR?= NILLNlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{WxNlg{OSd-Mke1NVI5OzF:L3G+
A673 cells MlrwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? M1HPZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY cells NF21RXNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?= NGPSdmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 cells M1jXepFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= MmfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 cells MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? NFzrV3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD cells MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> NWnDTI54RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH cells NVm3T|NZeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> NXfBSWtwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 cells Mn:xdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| M{HBc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) cells Mnv5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NH\nS|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 cells MnK0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NYjVWJFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 cells NH3ndGRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 cells NUK3SpRxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= NW[ze|ZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC cells NVTic4xQeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> NV\ico1qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 cells NIGyWXByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= MkiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
β-catenin / c-Myc / LEF1 / DVL2 / DVL3 / p-GSK3β; 

PubMed: 27926488     


RPMI8226, MM.1S and LP1 cells exposed with indicated concentrations of GSK126. Regulatory proteins in Wnt/β-catenin pathway were analyzed by immunoblotting.

XIAP / Survivin / MCL-1 / BID / BIM / BAX / BCL-xl/ Bcl-2; 

PubMed: 27926488     


Dose- and time-dependent effects of GSK126 on apoptosis-related proteins in RPMI8226, MM.1S and LP1 cells were detected by immunoblotting. Arrows indicates the specific bands of corresponding proteins.

H3K27Me3 / EZH2; 

PubMed: 28418882     


Increasing concentrations of GSK126 consistently decreased H3K27 me3 protein levels. After HEC50B and HEC1B cells were treated with various concentrations of GSK126 (0.1–10 μM) or 0.2% DMSO for 24 h, western blotting was performed for EZH2 and H3K27 me3.

27926488 28418882
Immunofluorescence
H3K27me3; 

PubMed: 25053977     


Representative images produced by immunostaining followed by fluorescence in situ hybridisation on RNA for H3K27me3 (green) and Xist (red) on female extraendoderm stem (XEN) cells (GHP7/9 cell line) treated or not with 2 μM GSK126 for 5 days. Arrowheads indicate the nuclear position of the inactive X chromosome coated with Xist RNA. The percentage of visible H3K27me3 accumulation on the Xist-coated X chromosome in each condition is indicated. n > 50. Scale bar = 5 μm.

25053977
Growth inhibition assay
Cell proliferation; 

PubMed: 29685965     


Antiproliferative effects of GSK126 on a panel of cancer cell lines, treated with 1, 10 and 25 µM of the compound for 4 or 5 days (MTS Cell Proliferation Assay). Error bars represent standard deviation. (Online version in colour.)

Cell viability; 

PubMed: 28418882     


After treatment with various concentrations of GSK126 (0.025–20 μM) for 8 days, five endometrial cancer cell lines were subjected to cell viability assay. Cell viability (%) was normalized using cells treated with 0.4% dimethyl sulfoxide (DMSO). The IC50 values of GSK126 in endometrial cancer cell lines ranged from 2.37-5.07 μM.

29685965 28418882
体内研究 在负荷KARPAS-422和Pfeiffer异种移植物的小鼠体内,GSK126 (150 mg/kg/d, i.p.)降低总体H3K27me3,增加基因表达,从而引起显著的肿瘤消退。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

EZH2 试验:

制备包含野生型或突变型EZH2的5个组分的PRC2复合物(Flag–EZH2,EED,SUZ12,AEBP2,RbAp48)。GSK126在DMSO中溶解,以0.6 nM到300 nM的浓度测试,终DMSO浓度为2.5%。体外实验中,相对于更倾向H3K27me0作为底物的野生型EZH2,EZH2 Y641倾向于H3K27me2作为底物,而对H3K27me0 或H3K27me1的活性很低。A677G不同于EZH2的野生型和Y641突变型,它有效地使H3K27me0,H3K27me1,和H3K27me2甲基化;因此,组蛋白H3多肽(残基21–44;终浓度10 μM)与 K27me0 (野生型,A677G EZH2),K27me1 (A677G EZH2),或K27me2 (A677G,Y641N,Y641C,Y641H,Y641S 和 Y641F EZH2)用作甲基转移酶底物。GSK126加入到板中,然后加入6 nM EZH2复合物和多肽。GSK126的效能处于或接近[SAM] = Km下进行的试验的紧密结合界限,IC50值在竞争性底物SMA相对其Km(7.5 μM SAM,而 SAM Km为0.3 μM)较高浓度下测量。在这些条件下,酶浓度的作用相对非常小,可以计算出Ki的精确估计值。反应通过[3H]-SAM起始,培养30分钟,加入500倍过量未标记的SAM淬灭反应,甲基化产物肽在磷酸纤维素过滤器上根据供应商提供的MSPH 多屏幕平板进行捕获。表观Ki值使用竞争性抑制剂的Cheng–Prusoff关系计算。IC50=Ki (1+[S]/Km)+[E]/2,其中E是酶,S为底物。
细胞实验:

[1]

- 合并
  • Cell lines: 46 淋巴瘤细胞系
  • Concentrations: 0~10 μM
  • Incubation Time: 6天
  • Method:

    所有细胞系的最优细胞接种根据经验确定,通过检测在384孔板式中宽范围的接种密度以确定可以增殖6天的试验条件。然后细胞以最佳接种密度接种24小时,再用20点两倍连续稀释的GSK126 或0.15% DMSO处理(一式两份)。板在37℃下在5% CO2中培养6天。然后将细胞用CellTiter-Glo (CTG)裂解,化学发光信号用TECAN Safire2酶标仪检测。此外,未处理板中的细胞在化合物加入(T0)时进行采集以定量初始细胞数。处理6天后得到的CTG值表示为T0值的百分比,并以化合物浓度为横坐标绘图。数据拟合为4参数方程以产生浓度反应曲线,并测定抑制50%生长(生长 IC50)的GSK126浓度。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 负荷 Pfeiffer 或 KARPAS-422 肿瘤的雌性米黄色 SCID 小鼠
  • Dosages: 150 mg/kg/day
  • Administration: i.p.
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 3 mg/mL warmed (5.69 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+corn oil
0.5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 526.67
化学式

C31H38N6O2

CAS号 1346574-57-9
储存条件 粉状
溶于溶剂
别名 GSK2816126A, GSK2816126

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02082977 Terminated Drug: GSK2816126 Cancer|Neoplasms GlaxoSmithKline April 24 2014 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you please suggest a vehicle for in vivo uses without oil?

  • 回答:

    S7061 could be dissolved in 4% DMSO+30% PEG 300+ddH2O (0.5mg/ml).

  • 问题 2:

    Does this drug require an activation step to be functional? For example, an acidic or basic environment.

  • 回答:

    GSK126 does not require an activation step to be functional.

Histone Methyltransferase Signaling Pathway Map

Tags: 购买GSK126 | GSK126供应商 | 采购GSK126 | GSK126价格 | GSK126生产 | 订购GSK126 | GSK126代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID